171 related articles for article (PubMed ID: 31869407)
21. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey.
Ellis MH; Lavi N; Vannucchi A; Harrison C
Thromb Res; 2014 Aug; 134(2):251-4. PubMed ID: 24842684
[TBL] [Abstract][Full Text] [Related]
22. Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy.
Sant'Antonio E; Borsani O; Camerini C; Botta C; Santoro M; Allegra A; Siragusa S
Blood Rev; 2022 Mar; 52():100903. PubMed ID: 34742614
[TBL] [Abstract][Full Text] [Related]
23. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.
Sørensen AL; Hasselbalch HC
Leuk Res; 2016 Feb; 41():27-35. PubMed ID: 26718091
[TBL] [Abstract][Full Text] [Related]
24. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
25. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
27. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
28. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
30. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
[TBL] [Abstract][Full Text] [Related]
31. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
[TBL] [Abstract][Full Text] [Related]
32. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Mattar MM; Nassef S; El Husseiny NM; El Masry MR; Salah M; Morad MA; Gawad AA
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e425-e429. PubMed ID: 31229378
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.
Potthoff A; Attia D; Pischke S; Mederacke I; Beutel G; Rifai K; Deterding K; Heiringhoff K; Klempnauer J; Strassburg CP; Manns MP; Bahr MJ
Liver Int; 2015 Aug; 35(8):2042-9. PubMed ID: 25736096
[TBL] [Abstract][Full Text] [Related]
35. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
Peseski AM; Saliba AN; Althouse SK; Sayar H
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):30-38. PubMed ID: 33607101
[TBL] [Abstract][Full Text] [Related]
36. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
37. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
Robinson SE; Harrison CN
Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
[TBL] [Abstract][Full Text] [Related]
38. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
39. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
Feng Y; Zhang Y; Shi J
Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
[TBL] [Abstract][Full Text] [Related]
40. Ten years of cerebral venous thrombosis: male gender and myeloproliferative neoplasm is associated with thrombotic recurrence in unprovoked events.
Lim HY; Ng C; Donnan G; Nandurkar H; Ho P
J Thromb Thrombolysis; 2016 Oct; 42(3):423-31. PubMed ID: 27085541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
